Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: GlobeNewswire
The Company's shares, which currently trade on NASDAQ, will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on July 22, 2019, under the symbol ENLV Tel-Aviv, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- ?Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the Tel Aviv Stock Exchange (TASE) approved the listing of its ordinary shares effective July 22, 2019, under the symbol ENLV. Enlivex has a current market capitalization of approximately US$220 Million, and is expected to join the TASE leading indices effective October 2019. The Company's ordinary shares will continue to trade on NASDAQ, and the Company will continue to comply with the reporting and disclosure requirements of the U.S. Securities and Exchanges Commission applicable to foreign private issuers. In the framework of the dual listing, the Company will not be required to submit additional reports beyond those required in the United States. Enlivex is developi
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.MarketBeat
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewswire
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
ENLV
Analyst Actions
- 9/27/24 - HC Wainwright
ENLV
Sec Filings
- 12/11/24 - Form 6-K
- 12/3/24 - Form 6-K
- 11/29/24 - Form 6-K
- ENLV's page on the SEC website